A Study of AMC6156 in People With Sarcopenia
Recruiting
Phase 2
Interventional Study
Sarcopenia in Elderly
Sarcopenia
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 65 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- Animuscure Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Voluntary participation with written informed consent
* Male ≥ 65 years or postmenopausal female
* Diagnosed with sarcopenia:
* ASM \< 7.0 kg/m² (men) or \< 5.4 kg/m² (women)
* Plus low handgrip strength or SPPB ≤ 9
* MNA screening score ≥ 8
* Body weight ≥ 35 kg, BMI between …
Contacts